AWM Investment Company’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

AWM Investment Company’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-666,661	Closed	-$3.89M	–	132
2022 Q4	$3.89M	Hold	666,661	–	–	0.56%	44
2022 Q3	$4.47M	Buy	666,661 +162,000	+32%	+$982K	0.68%	43
2022 Q2	$2.13M	Buy	+504,661	New	+$2M	0.33%	68
2017 Q2	–	Sell	-68,606	Closed	-$1.17M	–	101
2017 Q1	$1.17M	Sell	68,606 -41,394	-38%	-$496K	0.22%	68
2016 Q4	$1.13M	Buy	110,000 +10,000	+10%	+$91.4K	0.22%	77
2016 Q3	$1.01M	Hold	100,000	–	–	0.19%	81
2016 Q2	$1.12M	Hold	100,000	–	–	0.24%	76
2016 Q1	$1.37M	Buy	+100,000	New	+$1.44M	0.29%	67

AWM Investment Company's CNCE Position: Q1 2023 in Review

AWM Investment Company sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 666,661 shares — an estimated $3.89M sold.

AWM Investment Company first reported a position in CNCE in Q1 2016 and held it in 8 quarters. The position peaked at $4.47M in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

AWM Investment Company reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
AWM Investment Company sold 666,661 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3.89M.
AWM Investment Company first reported a position in Concert Pharmaceuticals, Inc. in Q1 2016 and held it in 8 quarters.
AWM Investment Company's Concert Pharmaceuticals, Inc. position peaked at $4.47M in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on AWM Investment Company's 13F filing for Q1 2023, filed 12 May 2023.